Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Secondary central nervous system lymphoma (SCNSL) is associated with poor prognosis and new therapeutic approaches are needed. The pivotal trial that led to US Food and Drug Administration (FDA) approval of axicabtagene ciloleucel excluded patients with SCNSL and human immunodeficiency virus. In this multi-institutional retrospective study, 14 SCNSL patients treated with axicabtagene ciloleucel, 3 of whom had human immunodeficiency virus, experienced rates of severe neurotoxicity and complete response of 32% and 58%, respectively. This is similar to rates observed in the pivotal ZUMA-1 trial that led to the approval of axi-cel at median follow-up of 5.9 months. Chimeric antigen receptor T-cell therapy is potentially a life-saving therapy for SCNSL patients and should not be withheld.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CJI.0000000000000416 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell-Eligible and -Naive Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
July 2025
Université Paris Cité, Hôpital Saint Louis, Assistance Publique - Hôpitaux de Paris, Hemato-oncologie, Inserm U1153, Paris, France.
Background: In the absence of a head-to-head trial of off-the-shelf subcutaneous epcoritamab, a novel CD3xCD20 bispecific antibody, versus chimeric antigen receptor T-cell therapy (CAR T), a matching-adjusted indirect comparison (MAIC) of epcoritamab versus axicabtagene ciloleucel (axi-cel) efficacy was conducted in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with ≥ 2 prior lines of systemic therapy.
Methods: The MAIC used epcoritamab patient-level data from EPCORE NHL-1 (NCT03625037; April 2023 data cutoff) and axi-cel aggregated data from ZUMA-1 (NCT02348216). Patients without prior CAR T were matched to the ZUMA-1 population; weighted regression models were used to estimate absolute differences in overall response rate (ORR) and complete response (CR) rate, and weighted Cox proportional-hazards models were used to estimate hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS).
From R-CHOP to Revolution: How CAR T-Cells, ADCs, and Bispecific Antibodies Are Transforming DLBCL Treatment.
Crit Rev Oncol Hematol
September 2025
Department of Hematology-Oncology, Hotel-Dieu de France, Beirut, Lebanon. Electronic address:
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive subtype of non-Hodgkin lymphoma, with R-CHOP as the standard first-line treatment. However, many patients experience relapse or refractory disease, prompting the need for new therapeutic approaches. Recent advances, including chimeric antigen receptor (CAR) T-cell therapies, antibody-drug conjugates (ADCs), bispecific antibodies (bsAbs), immunomodulators, and Exportin-1 (XPO-1) inhibitors have transformed treatment strategies.
View Article and Find Full Text PDFClinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell Therapy.
Curr Oncol
July 2025
Department of Medical Oncology, Inselspital-Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
FMC63-CAR T cell therapy targeting CD19 protein on malignant B-cells is effective in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), with complete response rates of 43-54%. Common germline variants of the immune-checkpoint regulator CTLA-4 may elicit different responses to CAR-T cell therapy. The gene single-nucleotide polymorphism rs231775 coding threonine or alanine at amino acid position 17 of the CTLA-4 protein was prevalent in 55% of the studied DLBCL patients.
View Article and Find Full Text PDFComparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.
Blood Adv
August 2025
Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Although 3 commercial CD19-targeted CAR T-cell therapies are available for large B-cell lymphoma (LBCL), no randomized clinical trials have compared their efficacy and safety. In this retrospective multicenter cohort study, we evaluated real-world clinical outcomes of patients with relapsed/refractory LBCL treated with axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), or lisocabtagene maraleucel (liso-cel). Between April 2016 and July 2024, 624 patients received CD19-targeted CAR T-cell therapies (344 axi-cel, 142 tisa-cel, and 138 liso-cel).
View Article and Find Full Text PDFPharmacoeconomic Profiles of Advanced Therapy Medicinal Products in Rare Diseases: A Systematic Review.
Healthcare (Basel)
August 2025
Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy.
: Advanced Therapy Medicinal Products (ATMPs) are innovative drugs based on genes, tissues, or cells that target rare and severe diseases. ATMPs have shown promising clinical outcomes but are associated with high costs, raising questions about cost-effectiveness. Hence, this systematic review aims to analyze the cost-effectiveness and cost-utility profiles of the European Medicines Agency-authorized ATMPs for treating rare diseases.
View Article and Find Full Text PDF